

Thomas Hughes, PhD has more than 24 years of experience in the biomedical and pharmaceutical research and development. Dr. Hughes is President and CEO of Zafgen, Inc – a biotech company focused on treatment of severe obesity and its related cardiometabolic risk factors,…more ›

Dr. Corey Goodman is a Founding Partner of venBio – a new life sciences strategic capital company working with Amgen, Baxter, and PPD. With a B.S. from Stanford University and Ph.D. from U.C. Berkeley, he spent 25 years as a biology professor at Stanford and Evan Rauch …more ›

Dr. Goodman became Chief Scientist and Deputy Commissioner for Science and Public Health of the FDA in 2009. He has broad responsibility for and engagement in leadership and coordination of the Agency’s cross-cutting scientific and public health efforts. From 2003-2009,…more ›

Larry is currently the Managing Director of 4iNNO, a leading consultancy on Open Innovation. 4iNNO also creates $1+ billion growth platforms for client companies. He has created a new model of Innovation that is being adopted by hundreds of companies around the world.…more ›

John J. Orloff, M.D. is the Chief Medical Officer and Senior Vice President, Global Development, for Novartis Pharma AG. In this position, Dr. Orloff is responsible for providing strategic and scientific leadership for all processes within Global Development, and for r…more ›

Bernard Munos is the founder of the InnoThink Center for Research in Biomedical Innovation, which was created to translate innovation research into better evidence-based business models for the pharmaceutical industry and its stakeholders. Before that, he was Advisor f…more ›

Sohini Chowdhury joined the Foundation after spending five years at the World Economic Forum in Geneva, Switzerland. As the Senior Community Manager of the Forum's Technology Pioneers program, she was responsible for annually selecting and integrating innovative bio…more ›

Lesa Mitchell is a vice president with the Kauffman Foundation. She has been responsible for the Foundation’s frontier work in understanding the policy levers that influence the advancement of innovation from universities into the commercial market and the new relation…more ›

Francois Nader has been president and chief executive officer of NPS Pharmaceuticals, Inc. since March 2008. Dr. Nader joined NPS in June 2006 and served as executive vice president and chief operating officer until March 2008. In that capacity, he was responsible for…more ›

G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Ch…more ›

Tariq Ghayur received a Ph.D in Immunology from McGill University, Montreal, Canada. He did his post-doctoral training at McGill (1986-’88) and Dana Farber Cancer Institute (1988-’90). He joined BASF Pharma (1990), which was acquired by Abbott Laboratories in 2000. He …more ›

Douglas Lowy is the Deputy Director of the National Cancer Institute (NCI) part of The National Institutes of Health, and the chief of the Laboratory of Cellular Oncology in the Center for Cancer Research. Dr. Lowy received his medical degree from New York University Sc…more ›

John Wilbanks works on open content, open data, and open innovation systems in the life sciences and sustainability. He has worked at Creative Commons, the Berkman Center for Internet & Society at Harvard University, MIT’s Computer Science and Artificial Intelligenc…more ›

Bruce Booth is a Partner in the Life Sciences group and joined Atlas Venture in 2005. He focuses on novel biopharmaceutical products, therapeutic platforms and innovative biomedical technologies. Bruce currently serves on the Boards of Atlas portfolio companies Avila, …more ›

Henry Chesbrough is Executive Director of the Center for Open Innovation at the Haas School of Business at UC Berkeley. Previously, he was an assistant professor of business administration, and the Class of 1961 Fellow at the Harvard Business School. He holds a Ph.D. i…more ›
The World Pharma Innovation Congress USA attracts senior executives from pharma and biotech, who are committed to reshaping the pharma industry to drive R&D innovation. It is the place where innovation is showcased, learning is done and new contacts are made.
The World Pharma Innovation Congress USA provides an unrivalled platform to revolutionize open innovation for the drug industry. Discussing business, external technology sourcing, talent management and successful corporate open innovation models, it is the perfect opportunity to identify and approach new business prospects.
Investors will attend Biotech Investment World to learn how to invest in this promising sector and how to identify emerging biotech companies that will generate ROI.
• How to make money from biotech investment
• How to build partnerships that create opportunity
• How to select high return biotech investments
• How to identify best sector bets for 2012 and beyond
Biotech applications are now available!